CTRI/2024/03/064630尚未招募3 期
A double-blind, randomized, placebo-controlled trial evaluating the efficacy of individualized homoeopathic medicine selected by using polarity analysis in improving chronic primary pain of heel in adults - NI
The Calcutta Homoeopathic Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with chronic primary pain of heel (ICD code- 11, MG 30.0). Heel pain persist for at least 3 months or more and absence of any bony deformity of foot on X-ray.
- •2. Age: 18 – 65years.
- •3. Patients of either sex including transgenders
- •4. Patients already undergoing regular oral or topical analgesics or NSAID therapy for painful episodes of chronic primary pain of heel, provided the medications are stopped completely at least 2 weeks prior study entry.
- •5. Cases eligible for polarity analysis. Patient having at least 5 polar symptoms and 10 indicated remedies under a rubric.
排除标准
- •1. Not providing with informed consent voluntarily
- •2. Those cases suffering from uncontrolled systemic illness or life-threatening infections, suffering from calcaneal spur or any bony deformity or foot pathology.
- •3. Self-reported joint disorders (e.g., specific arthropathy, hyperuricaemia and/or gout, fracture or injury to the bones, bone tumour, joint or skin
- •infections, joint prostheses of the lower limbs, rheumatoid arthritis)
- •4. Steroid injections within 2 weeks before study entry
- •5. Recent significant heel surgery within last 6 months
- •6. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life
- •7. Pregnancy, puerperium, lactation
- •8. Vulnerable population – Unconscious, non-ambulatory, too ill for consultation, differently abled, terminally ill or critically ill patients,
- •mentally disabled people
- •9. Substance abuse and or dependence
- •10. Self-reported immune-compromised state
- •11. Undergoing homoeopathic treatment for any chronic disease within last 6 months, and
- •12. Simultaneous participation in any other clinical trial
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of early the treatment with Eplerenone in patients with acute myocardial infarction.Estudio doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia del tratamiento precoz con Eplerenona en pacientes con infarto agudo de miocardio. - NAInfarto agudo de miocardioMedDRA version: 13Level: LLTClassification code 10000891Term: Infarto agudo de miocardioEUCTR2010-019844-38-ESPfizer, S.A612
进行中（未招募）
1 期
A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsyprotocadherin 19 (PCDH19)-related epilepsyMedDRA version: 20.0Level: LLTClassification code 10032061Term: Other forms of epilepsySystem Organ Class: 100000004852EUCTR2018-004496-12-GBMarinus Pharmaceuticals, Inc.70
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia (DMF-FA-201).Friedreich's AtaxiaMedDRA version: 20.0Level: PTClassification code: 10017374Term: Friedreich's ataxia Class: 100000004850CTIS2022-503016-16-00Dipartimento Di Neuroscienze E Scienze Riproduttive Ed Odontostomatologiche Universita Degli Studi Di Napoli Federico II40
进行中（未招募）
1 期
A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsyprotocadherin 19 (PCDH19)-related epilepsyMedDRA version: 20.0Level: LLTClassification code 10032062Term: Other forms of epilepsy, with intractable epilepsySystem Organ Class: 100000004852EUCTR2018-004496-12-ITMarinus Pharmaceuticals, Inc70
尚未招募
2 期
Homeopathic medicines for wrist ganglioCTRI/2024/03/063897D. N. De Homoeopathic Medical College and Hospital